A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called
beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor
(GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in
complete remission. The combination may be effective because the different parts of the
treatment work to strengthen the immune system's response against cancer cells in different
ways.